Exforge

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

valsartan, amlodipine (as amlodipine besilate)

Available from:

Novartis Europharm Limited

ATC code:

C09DB01

INN (International Name):

amlodipine, valsartan

Therapeutic group:

Sredstva, ki delujejo na sistem renin-angiotenzin

Therapeutic area:

Hipertenzija

Therapeutic indications:

Zdravljenje esencialne hipertenzije. Exforge je indicirana pri bolnikih, katerih krvni tlak ni ustrezno nadzorovan na amlodipine ali valsartan monotherapy.

Product summary:

Revision: 31

Authorization status:

Pooblaščeni

Authorization date:

2007-01-16

Patient Information leaflet

                                29
9.
POSEBNA NAVODILA ZA SHRANJEVANJE
Shranjujte pri temperaturi do 30 °C.
Shranjujte v originalni ovojnini za zagotovitev zaščite pred vlago.
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Novartis Europharm Limited
Vista Building
Elm Park, Merrion Road
Dublin 4
Irska
12.
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET
EU/1/06/370/001
7 filmsko obloženih tablet
EU/1/06/370/002
14 filmsko obloženih tablet
EU/1/06/370/003
28 filmsko obloženih tablet
EU/1/06/370/004
30 filmsko obloženih tablet
EU/1/06/370/005
56 filmsko obloženih tablet
EU/1/06/370/006
90 filmsko obloženih tablet
EU/1/06/370/007
98 filmsko obloženih tablet
EU/1/06/370/008
280 filmsko obloženih tablet
EU/1/06/370/025
56x1 filmsko obložena tableta (za enkratni odmerek)
EU/1/06/370/026
98x1 filmsko obložena tableta (za enkratni odmerek)
EU/1/06/370/027
280x1 filmsko obložena tableta (za enkratni odmerek)
13.
ŠTEVILKA SERIJE
Lot
14.
NAČIN IZDAJANJA ZDRAVILA
Predpisovanje in izdaja zdravila je le na recept.
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
Exforge 5 mg/80 mg
30
17.
EDINSTVENA OZNAKA – DVODIMENZIONALNA ČRTNA KODA_ _
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
18.
EDINSTVENA OZNAKA – V BERLJIVI OBLIKI_ _
PC
SN
NN
31
PODATKI NA ZUNANJI OVOJNINI
VMESNA ŠKATLA SKUPNEGA PAKIRANJA (BREZ “BLUE BOX” PODATKOV)
1.
IME ZDRAVILA
Exforge 5 mg/80 mg filmsko obložene tablete
amlodipin/valsartan
2.
NAVEDBA ENE ALI VEČ UČINKOVIN
Ena tableta vsebuje 5 mg amlodipina (v obliki amlodipinijevega
besilata) in 80 mg valsartana.
3.
SEZNAM POMOŽNIH SNOVI
4.
FARMACEVTSKA OBLIKA IN VSEBINA
filmsko obložena tableta
70 filmsko obloženih tablet Del skupnega pakiranja. Ni namenjen
ločeni prodaji.
14 filmsko obloženih tablet. Del skupnega pakiranja. Ni namenjen
ločeni prodaji.
5.
POSTOPEK IN POT(I) UPORABE ZDRAVILA
_ _
Pred uporabo preberite priloženo navodilo!
Peroralna uporaba.
6
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1.
IME ZDRAVILA
Exforge 5 mg/80 mg filmsko obložene tablete
Exforge 5 mg/160 mg filmsko obložene tablete
Exforge 10 mg/160 mg filmsko obložene tablete
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Exforge 5 mg/80 mg filmsko obložene tablete
Ena filmsko obložena tableta vsebuje 5 mg amlodipina (v obliki
amlodipinijevega besilata) in 80 mg
valsartana.
Exforge 5 mg/160 mg filmsko obložene tablete
Ena filmsko obložena tableta vsebuje 5 mg amlodipina (v obliki
amlodipinijevega besilata) in 160 mg
valsartana.
Exforge 10 mg/160 mg filmsko obložene tablete
Ena filmsko obložena tableta vsebuje 10 mg amlodipina (v obliki
amlodipinijevega besilata) in
160 mg valsartana.
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
Filmsko obložena tableta.
Exforge 5 mg/80 mg filmsko obložene tablete
Temnorumene, okrogle filmsko obložene tablete s poševnimi robovi, ki
imajo na eni strani oznako
“NVR” in na drugi “NV”. Približna velikost: premer 8,20 mm.
Exforge 5 mg/160 mg filmsko obložene tablete
Temnorumene, ovalne filmsko obložene tablete, ki imajo na eni strani
oznako “NVR” in na drugi
“ECE”. Približna velikost: 14,2 mm (dolžina) x 5,7 mm (širina).
Exforge 10 mg/160 mg filmsko obložene tablete
Svetlorumene, ovalne filmsko obložene tablete, ki imajo na eni strani
oznako “NVR” in na drugi
“UIC”. Približna velikost: 14,2 mm (dolžina) x 5,7 mm (širina).
4.
KLINIČNI PODATKI
4.1
TERAPEVTSKE INDIKACIJE
Zdravljenje esencialne hipertenzije.
Zdravilo Exforge je indicirano pri odraslih, pri katerih krvni tlak ni
ustrezno urejen ob monoterapiji z
amlodipinom ali valsartanom.
3
4.2
ODMERJANJE IN NAČIN UPORABE
Odmerjanje
Priporočeni odmerek zdravila Exforge je ena tableta na dan.
Zdravilo Exforge 5 mg/80 mg lahko uporabite pri bolnikih, pri katerih
krvni tlak ni ustrezno urejen
samo s 5 mg amlodipina ali z 80 mg valsartana.
Zdravilo Exforge 5 mg/160 mg lahko uporabite pri bolnikih, pri katerih
krvni tlak ni ustrezno urejen
sa
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 11-11-2022
Summary of Product characteristics Summary of Product characteristics Bulgarian 11-11-2022
Public Assessment Report Public Assessment Report Bulgarian 05-08-2015
Patient Information leaflet Patient Information leaflet Spanish 11-11-2022
Public Assessment Report Public Assessment Report Spanish 05-08-2015
Patient Information leaflet Patient Information leaflet Czech 11-11-2022
Public Assessment Report Public Assessment Report Czech 05-08-2015
Patient Information leaflet Patient Information leaflet Danish 11-11-2022
Public Assessment Report Public Assessment Report Danish 05-08-2015
Patient Information leaflet Patient Information leaflet German 11-11-2022
Public Assessment Report Public Assessment Report German 05-08-2015
Patient Information leaflet Patient Information leaflet Estonian 11-11-2022
Public Assessment Report Public Assessment Report Estonian 05-08-2015
Patient Information leaflet Patient Information leaflet Greek 11-11-2022
Public Assessment Report Public Assessment Report Greek 05-08-2015
Patient Information leaflet Patient Information leaflet English 11-11-2022
Public Assessment Report Public Assessment Report English 05-08-2015
Patient Information leaflet Patient Information leaflet French 11-11-2022
Public Assessment Report Public Assessment Report French 05-08-2015
Patient Information leaflet Patient Information leaflet Italian 11-11-2022
Public Assessment Report Public Assessment Report Italian 05-08-2015
Patient Information leaflet Patient Information leaflet Latvian 11-11-2022
Public Assessment Report Public Assessment Report Latvian 05-08-2015
Patient Information leaflet Patient Information leaflet Lithuanian 11-11-2022
Summary of Product characteristics Summary of Product characteristics Lithuanian 11-11-2022
Public Assessment Report Public Assessment Report Lithuanian 05-08-2015
Patient Information leaflet Patient Information leaflet Hungarian 11-11-2022
Summary of Product characteristics Summary of Product characteristics Hungarian 11-11-2022
Public Assessment Report Public Assessment Report Hungarian 05-08-2015
Patient Information leaflet Patient Information leaflet Maltese 11-11-2022
Public Assessment Report Public Assessment Report Maltese 05-08-2015
Patient Information leaflet Patient Information leaflet Dutch 11-11-2022
Public Assessment Report Public Assessment Report Dutch 05-08-2015
Patient Information leaflet Patient Information leaflet Polish 11-11-2022
Public Assessment Report Public Assessment Report Polish 05-08-2015
Patient Information leaflet Patient Information leaflet Portuguese 11-11-2022
Summary of Product characteristics Summary of Product characteristics Portuguese 11-11-2022
Public Assessment Report Public Assessment Report Portuguese 05-08-2015
Patient Information leaflet Patient Information leaflet Romanian 11-11-2022
Public Assessment Report Public Assessment Report Romanian 05-08-2015
Patient Information leaflet Patient Information leaflet Slovak 11-11-2022
Public Assessment Report Public Assessment Report Slovak 05-08-2015
Patient Information leaflet Patient Information leaflet Finnish 11-11-2022
Public Assessment Report Public Assessment Report Finnish 05-08-2015
Patient Information leaflet Patient Information leaflet Swedish 11-11-2022
Public Assessment Report Public Assessment Report Swedish 05-08-2015
Patient Information leaflet Patient Information leaflet Norwegian 11-11-2022
Summary of Product characteristics Summary of Product characteristics Norwegian 11-11-2022
Patient Information leaflet Patient Information leaflet Icelandic 11-11-2022
Summary of Product characteristics Summary of Product characteristics Icelandic 11-11-2022
Patient Information leaflet Patient Information leaflet Croatian 11-11-2022
Public Assessment Report Public Assessment Report Croatian 05-08-2015

Search alerts related to this product

View documents history